8-K: Phio Pharmaceuticals Files for At-the-Market Offering

Phio Pharmaceuticals Corp. has entered into an At The Market Offering Agreement to sell up to $6.36 million in common stock.

Summary

• Phio Pharmaceuticals Corp. has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, as sales agent.
• The company may offer and sell shares of its common stock, with a total offering size of up to $6,360,000.
• The offering is registered under the company's existing Form S-3 shelf registration statement.
• H.C. Wainwright & Co., LLC will act as the sales agent, using commercially reasonable efforts to sell the shares.
• The sales agent will receive a commission of 3.0% of the gross proceeds from each sale.
• The company has agreed to reimburse the sales agent for certain expenses, including up to $75,000 for legal counsel fees.
• Sales will be conducted as 'at the market' offerings, with the company setting the parameters for sales.
• The company is not obligated to sell any shares and can suspend or terminate the agreement at any time.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it provides access to capital, it also introduces potential dilution for existing shareholders.

Positives

• Provides access to capital up to $6.36 million through an at-the-market offering.
• Flexibility to sell shares as market conditions allow, without a fixed price commitment.
• Established sales agent (H.C. Wainwright & Co., LLC) with experience in such offerings.
• Registration statement is already effective, allowing for quicker execution of sales.

Negatives

• Potential for dilution to existing shareholders as new shares are issued.
• The offering price will be determined by market conditions, which could be unfavorable.
• Commissions and expenses associated with the offering reduce net proceeds.
• No assurance that any shares will be sold or the total amount raised.

Risks

• Market volatility could negatively impact the price at which shares are sold.
• The company's ability to raise the full $6.36 million is not guaranteed.
• Potential for increased share price volatility due to ongoing sales.
• Dilution of existing shareholders' equity if a significant number of shares are sold.

Future Outlook

The company may offer and sell shares of its common stock from time to time through the sales agent, up to a maximum aggregate offering price of $6,360,000. The company has the flexibility to suspend or terminate the offering at any time.

Industry Context

StockSavvy.ai notes that 'At The Market' (ATM) offerings are a common method for biotechnology and pharmaceutical companies to access capital in a flexible manner, allowing them to sell shares opportunistically based on market conditions rather than through a fixed-price underwritten offering.

Stakeholder Impact

• Shareholders may experience dilution of their ownership percentage and potential decrease in share price due to the offering.
• The company gains access to capital, which could be used for operations, research and development, or other corporate purposes.

Next Steps

• The company may begin offering and selling shares of its common stock through H.C. Wainwright & Co., LLC.
• The company will receive gross proceeds from any sales, less the sales agent's commission and expenses.

Key Dates

Recommendation

The filing indicates a capital raise through an ATM offering, which provides financial flexibility but also carries the risk of dilution. Without further information on the use of proceeds or the company's financial performance, a 'hold' recommendation is prudent for existing investors, while new investors should carefully consider the dilution risk and the company's underlying business prospects.

Keywords

At The Market Offering, ATM Offering, Equity Financing, Common Stock, SEC Filing, Form 8-K, H.C. Wainwright & Co., Phio Pharmaceuticals